JP2023546300A5 - - Google Patents

Info

Publication number
JP2023546300A5
JP2023546300A5 JP2023548545A JP2023548545A JP2023546300A5 JP 2023546300 A5 JP2023546300 A5 JP 2023546300A5 JP 2023548545 A JP2023548545 A JP 2023548545A JP 2023548545 A JP2023548545 A JP 2023548545A JP 2023546300 A5 JP2023546300 A5 JP 2023546300A5
Authority
JP
Japan
Prior art keywords
hlas
complex
interrogated
inhibited
inducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548545A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546300A (ja
Filing date
Publication date
Priority claimed from GBGB2016659.1A external-priority patent/GB202016659D0/en
Priority claimed from GBGB2101665.4A external-priority patent/GB202101665D0/en
Application filed filed Critical
Priority claimed from PCT/US2021/055682 external-priority patent/WO2022087019A1/en
Publication of JP2023546300A publication Critical patent/JP2023546300A/ja
Publication of JP2023546300A5 publication Critical patent/JP2023546300A5/ja
Pending legal-status Critical Current

Links

JP2023548545A 2020-10-20 2021-10-19 細胞治療のための方法および組成物 Pending JP2023546300A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2016659.1A GB202016659D0 (en) 2020-10-20 2020-10-20 Methods and compositions for cellular therapy
GB2016659.1 2020-10-20
GB2101665.4 2021-02-05
GBGB2101665.4A GB202101665D0 (en) 2021-02-05 2021-02-05 Methods and compositions for cellular therapy
PCT/US2021/055682 WO2022087019A1 (en) 2020-10-20 2021-10-19 Methods and compositions for cellular therapy

Publications (2)

Publication Number Publication Date
JP2023546300A JP2023546300A (ja) 2023-11-01
JP2023546300A5 true JP2023546300A5 (https=) 2024-10-25

Family

ID=81290046

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548545A Pending JP2023546300A (ja) 2020-10-20 2021-10-19 細胞治療のための方法および組成物

Country Status (8)

Country Link
US (1) US20240124551A1 (https=)
EP (1) EP4232468A4 (https=)
JP (1) JP2023546300A (https=)
KR (1) KR20230110258A (https=)
AU (1) AU2021364550A1 (https=)
CA (1) CA3196346A1 (https=)
GB (1) GB2619410A (https=)
WO (1) WO2022087019A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3965829A4 (en) 2019-05-06 2023-05-24 Malcolm, Thomas ADAPTED HYPOIMMUNE NANOVESICULAR DELIVERY SYSTEM FOR CANCER TUMORS
GB202205771D0 (en) * 2022-04-20 2022-06-01 Replay Holdings Llc Methods and compositions for cellular therapy
GB202316281D0 (en) * 2023-10-24 2023-12-06 Replay Holdings Inc Methods and compositions for modulating immune cell activity in cellular therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004314A1 (en) * 1994-07-29 1996-02-15 Dade International, Inc. Mhc complexes and uses thereof
US6211342B1 (en) * 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
GB0107628D0 (en) * 2001-03-27 2001-05-16 Avidex Ltd Substances
GB0115071D0 (en) * 2001-06-20 2001-08-15 Avidex Ltd Substances
US8895020B2 (en) * 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
US9765330B1 (en) * 2015-01-09 2017-09-19 Nant Holdings Ip, Llc Compositions and methods for reduction of allograft recognition and rejection
WO2018089661A1 (en) * 2016-11-09 2018-05-17 La Jolla Institute For Allergy And Immunology Use of c-terminally extended peptides to disrupt inhibitor nk cell receptor interactions with mhc i
JP2020505025A (ja) * 2017-01-13 2020-02-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫工学的な改変をした多能性細胞
RU2764620C2 (ru) * 2018-07-10 2022-01-18 Общество С Ограниченной Ответственностью "Бетарут" Способ и устройство жидкой ковки двойного действия
US12331318B2 (en) * 2018-07-13 2025-06-17 Lothar Germeroth Non-immunogenic engineered tissue and methods of producing and using the same
US11232096B2 (en) * 2018-09-06 2022-01-25 Optumsoft, Inc. Automatic generation of an efficient rule set implementation

Similar Documents

Publication Publication Date Title
JP2023546300A5 (https=)
JP2022543009A5 (https=)
JP1725653S (ja) トラベルオーガナイザー
JP2006516528A5 (https=)
JP2019515674A5 (https=)
JP2022538215A5 (https=)
JP2004538039A5 (https=)
JP2007518723A5 (https=)
JP2021129286A5 (https=)
JP2021533273A5 (https=)
JP2024507827A5 (https=)
JP2013501834A5 (https=)
JP2022540353A5 (https=)
JP2017092104A5 (https=)
JP2023508938A5 (https=)
JP2007510403A5 (https=)
JP2021514452A5 (https=)
JP2023509880A5 (https=)
JP2022507958A5 (https=)
JP2017061668A5 (https=)
JP2017528146A5 (https=)
JP2005534326A5 (https=)
JP2026004274A5 (https=)
JP2009055850A5 (https=)
CN111247131A (zh) 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物